Home › NDC Lookup › Ingredients › Acetaminophen, Dextromethorphan Hbr ,Gua... › 57896-0596-08
🧴image loading
(from DailyMed)

Geri Care Tussin CF Max Acetaminophen, Dextromethorphan HBr, Guaifenesin 650 mg/20mL; 20 mg/20mL; 400 mg/20mL Liquid, 237 mL — NDC 57896-596-08 (Billing 57896-0596-08)

by GERI-CARE PHARMACEUTICAL CORP · 237 mL in 1 BOTTLE

This is a package of 237 mL of Geri Care Tussin CF Max Acetaminophen, Dextromethorphan HBr, Guaifenesin 650 mg/20mL; 20 mg/20mL; 400 mg/20mL Liquid from GERI-CARE PHARMACEUTICAL CORP, marketed since Dec 2025 and currently FDA-listed. It is this product's only package size.

NDC 57896-0596-08
🏷️ FDA NDC (as labeled) 57896-596-08 billing pads the product segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 57896-596-08
Product NDC 57896-596
11-digit billing NDC 57896059608
NCPDP billing unit ML — per mL (volume)
RxCUI 2680300
UNII 362O9ITL9D, 9D2RTI9KYH, 495W7451VQ
Application # M012
SPL Set ID 4744669c-7f33-e35f-e063-6394a90a79b7
Established class (EPC) Expectorant
Physiologic effect Decreased Respiratory Secretion Viscosity; Increased Respiratory Secretions
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2025-12-01
Route ORAL
Dosage form LIQUID
Substance ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 087618
GCN 57598
HICL code 000212
Ingredient (HICL) Guaifenesin/Dm/Acetaminophen
HIC1 code B
Therapeutic class — broad (HIC1) Respiratory System
HIC2 code B4
Therapeutic class — intermediate (HIC2) Drugs Affecting The Trachea And Bronchi (Contin.1)
HIC3 code B4B
Therapeutic class — specific (HIC3) Non-Opioid Antitussive-Analgesic-Expectorant Comb.
AHFS code 28:08.16.00
AHFS class Non-Opioid Analgesics
FDB label name TUSSIN CF MAX MULTI-SYMPTOM
FDB brand name Tussin Cf Max Multi-Symptom
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 087618
  • GCN: 57598
  • HICL (First Databank): 000212
  • AHFS class code: 28:08.16.00
  • RxCUI (RxNorm): 2680300
Why two NDCs? The FDA registers this code as 57896-596-08 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 57896-0596-08. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Anilides class.

Drug family (ATC) Anilides
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name TUSSIN CF MAX MULTI-SYMPTOM Ingredient Guaifenesin/Dm/Acetaminophen
🧪 What is this product?

Geri Care Tussin CF Max is an oral liquid cough and cold product sold over the counter under FDA's OTC monograph rules. It contains acetaminophen, which is commonly used to reduce fever and relieve pain; dextromethorphan, a cough suppressant typically used to reduce coughing; and guaifenesin, an expectorant generally used to help thin mucus and make coughs more productive. This combination is intended for people seeking relief from multiple cold symptoms.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
57896-0596-08 You're viewing this Main listing 237 mL in 1 BOTTLE 2025-12-01 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Leader Tussin Cf 650 mg/20mL; 20 mg/20mL; 400 mg/20mL 70000-0739-01 Cardinal 1 bottle $0.025 — Availability likely —
Robitussin Maximum Strength Severe Multi-Symptom Cough Cold Flu 650 mg/20mL; 20 mg/20mL; 400 mg/20mL 00031-0100-04 Haleon 1 bottle — — FDA listed —
Good Sense Tussin 650 mg/20mL; 20 mg/20mL; 400 mg/20mL 00113-2009-34 L. 1 bottle — — FDA listed —
Tussin Severe 650 mg/20mL; 20 mg/20mL; 400 mg/20mL 42507-0581-26 HyVee 1 bottle — — FDA listed —
CVS PHARMACY MS Adult Severe Multi Symptom Cough Cold Flu 650 mg/20mL; 20 mg/20mL; 400 mg/20mL 51316-0089-08 CVS 1 bottle — — FDA listed —
Severe Cough Cold And Flu 650 mg/20mL; 20 mg/20mL; 400 mg/20mL 51316-0189-26 CVS 1 bottle — — FDA listed —
Geri Care Tussin CF Max 650 mg/20mL; 20 mg/20mL; 400 mg/20mLthis 57896-0596-08 GERI-CARE 237 ml — — FDA listed —
Rompe Pecho Max 650 mg/20mL; 20 mg/20mL; 400 mg/20mL 58593-0005-08 Efficient 237 ml — — FDA listed —
Topcare Tussin Cf Max 650 mg/20mL; 20 mg/20mL; 400 mg/20mL 76162-0198-26 Topco 1 bottle — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2025
On the market since
Dec 2025
📍
2026
Currently FDA-listed
1 year listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerGERI-CARE PHARMACEUTICAL CORP
FDA applicationM012 (OTC MONOGRAPH DRUG)
Labeler code57896
First marketedDec 2025
Product typeHuman Otc Drug
Portfolio45 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 46 words ▾

Uses temporarily relieves these symptoms occurring with a cold or flu: cough due to minor throat and bronchial irritation minor aches and pains sore throat headache temporarily reduces fever helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tunes and make coughs more productive

⏱️ Dosage and Administration 64 words ▾

Directions mL = mililiter do not take more tha 6 doses in any 24-hour period do not exceed recommended dosage. Taking more than the recommeded dose (overdose) may cause serious liver damage measure only with dosing cup provided keep dosing cup with product adults and children 12 years and over: 20 mL every 4 hours children under 12 years of age: do not use

⚠️ Warnings ~1 min read ▾

Warnings Liver warning: This product contains acetaminophen. Severe liver damage may occur if you take more than 6 doses in any 24-hour period, which is the maximum daily amount with other drugs containing acetaminophen 3 or more alcoholic drinks every day while using this product Allergy alert: Acetaminophen may cause severe skin reactions. Symptoms may include skin reddening blisters rash If skin reaction occurs, stop use and seek medical help right away Sore throat warning: If sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly.

Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product with any other drug containing acetaminophen (prescription or nonprescritpion), if you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist. Ask a doctor before use if you have liver disease cough that occurs with too much phlegm (mucus) a breathing problem or chronic cough that lasts or as occurs with smoking, asthma, chronic bronchitis, or emphysema Ask a doctor or pharmacist before use if you are taking the blood thinning drug warfarin taking any other pain reliever/fever reducer Stop use and ask a doctor if pain or cough gets worse or lasts more than 7 days fever gets worse or lasts more tha 3 days redness or swelling is present new symptoms occur cough comes back or occurs with rash or headhache that lasts These could be sign of a serious condition.

🧪 Active Ingredient 16 words ▾

Active Ingredients (in each 20 mL) Acetaminophen 650 mg Dextromethorphan HBr 20 mg Guaifenesin 400 mg

🧪 Inactive Ingredients 24 words ▾

Inactive ingredients: artificial and natural flavor, citric acid, FD&C #40, hyroxyethyl cellulose, menthol, methylparaben, polyethylene glycol, propylene glycol, propylparaben, purified water, sodium citrate, sucralose

🎯 Purpose 7 words ▾

Purpose Pain reliever/fever reducer Cough Suppressant Expectorant

🤰 If Pregnant or Breast-Feeding 10 words ▾

If pregnant or breast-feeding, ask a health professional before use.

📄 Keep Out of Reach of Children 6 words ▾

Keep out of reach of children.

📄 Questions or Comments 4 words ▾

Questions or comments: 1-800-540-3765

📄 Package Label / Principal Display Panel 1 words ▾

GercareTussnCFMAX

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Acetaminophen, Dextromethorphan HBr, Guaifenesin — the ingredient across all brands.

Top reported reactions

Fatigue34
Dyspnoea27
Pneumonia27
Nausea26
Pain25
Fall22
Covid-1920

Age at onset

Adult41
Elderly35

Reporter sex

439 reports
Male · 35%
Female · 64%
Unknown · 1%

Serious outcomes

Hospitalization115
Death29
Life-threatening11
Disabling8
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 62 23
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Over-the-counter (OTC) product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by GERI-CARE PHARMACEUTICAL CORP. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
GERI-CARE PHARMACEUTICAL CORP is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 57896-0591-08 · GERI-CARE 57896-0615-12 · GERI-CARE →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.